Myocarditis: Diagnosis and treatment

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 6, 2012, Pages 637-651

  Guglin, Maya ^a   Nallamshetty, Leelakrishna ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cardiac magnetic resonance; Cardiomyopathy; Heart failure; Myocarditis

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GADOLINIUM; IMMUNOGLOBULIN; LOOP DIURETIC AGENT; OKT 3; PLACEBO; PREDNISONE; SPIRONOLACTONE; STEROID;

ATHLETE; BIVENTRICULAR ASSIST DEVICE; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EDEMA; EOSINOPHILIC MYOCARDITIS; EXTRACORPOREAL OXYGENATION; FULMINANT MYOCARDITIS; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; HYPEREMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL MYOCARDITIS; LYMPHOCYTIC MYOCARDITIS; MYOCARDITIS; NONISCHEMIC CARDIOMYOPATHY; POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; TISSUE NECROSIS; VIRUS GENOME;

EID: 84870297811     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0204-7     Document Type: Review

References (64)

1. Friman G, Wesslen L, Fohlman J. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J. 1995;16 (Suppl O):36-41. (Pubitemid 26082341)
2. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 2006;92:316-20.
3. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol. 1991;68:1388-92.
4. Kaji M, Kuno H, Turu T, et al. Elevated serum myosin light chain I in influenza patients. Intern Med. 2001;40:594-7. (Pubitemid 33611891)
5. Eckart RE, Love SS, Atwood JE, et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol. 2004;44:201-5. (Pubitemid 38968484)
6. Cooper Jr LT. Myocarditis. N Eng J Med. 2009;360:1526-38.
7. Dec Jr GW, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Eng J Med. 1985;312:885-90. (Pubitemid 15105673)
8. Pankuweit S, Moll R, Baandrup U, et al. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol. 2003;34:497-503. (Pubitemid 36666817)
9. Corssmit EP, Trip MD, Durrer JD. Loffler's endomyocarditis in the idiopathic hypereosinophilic syndrome. Cardiology. 1999;91:272-6. (Pubitemid 29502093)
10. Vinit J, Bielefeld P, Muller G, et al. Heart involvement in Churg-Strauss syndrome: retrospective study in French Burgundy population in past 10 years. Eur J Intern Med. 2010;21:341-6.
11. Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation. 2002;105:2611-8. (Pubitemid 34596037)
12. Anderson DW, Virmani R, Reilly JM, et al. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol. 1988;11:792-9. (Pubitemid 18092188)
13. Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect. 2000;40:282-4. (Pubitemid 30447185)
14. Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122:900-9.
15. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:3-14.
16. Shanes JG, Ghali J, Billingham ME, et al. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation. 1987;75:401-5. (Pubitemid 17007347)
17. Archard LC, Richardson PJ, Olsen EG, et al. The role of Coxsackie B viruses in the pathogenesis of myocarditis, dilated cardiomyopathy and inflammatory muscle disease. Biochem Soc Symp. 1987;53:51-62.
18. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc. 1989;64:1235-45. (Pubitemid 20005759)
19. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113:593-5.
20. Lurz P, Eitel I, Adam J, et al. Diagnostic performance of CMR imaging compared with emb in patients with suspected myocarditis. ACC. 2012;5:513-24.
21. Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation. 1994;90:330-9. (Pubitemid 24203696)
22. Mahfoud F, Gartner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32:897-903.
23. Stewart GC, Lopez-Molina J, Gottumukkala RV, et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Failure. 2011;4:71-8.
24. Verhaert D, Thavendiranathan P, Giri S, et al. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC. 2011;4:269-78.
25. Giri S, Chung YC, Merchant A, et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56
26. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475-87.
27. Li HS, Ligons DL, Rose NR. Genetic complexity of autoimmune myocarditis. Autoimmun Rev. 2008;7:168-73.
28. Brett NJ, Strugnell WE, Slaughter RE. Acute myocarditis demonstrated on CT coronary angiography with MRI correlation. Circ Cardiovasc Imaging. 2011;4: e5-6.
29. Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1815-22. (Pubitemid 40779862)
30. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250-8. (Pubitemid 38379570)
31. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 1997;95:163-8. (Pubitemid 27029958)
32. Morgera T, Di Lenarda A, Dreas L, et al. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J. 1992;124:455-67.
33. Ukena C, Mahfoud F, Kindermann I, et al. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Failure. 2011;13:398-405.
34. Grun S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59:1604-15. .
35. Matsumori A, Kawai C. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/ 2 mice with myocarditis caused by encephalomyocarditis virus. Circulation. 1982;66:355-60. (Pubitemid 12084986)
36. Xiong D, Yajima T, Lim BK, et al. Inducible cardiacrestricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation. 2007;115:94-102. (Pubitemid 46058616)
37. Keeling PJ, Jeffery S, Caforio AL, et al. Similar prevalence of enteroviral genome within the myocardium from patients with idiopathic dilated cardiomyopathy and controls by the polymerase chain reaction. Br Heart J. 1992;68:554-9. (Pubitemid 23001731)
38. Why HJ, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994;89:2582-9. (Pubitemid 24173674)
39. D'Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85:499-504. (Pubitemid 32973488)
40. Spodick DH. Eosinophilic myocarditis. Mayo Clin Proc. 1997;72:996. (Pubitemid 127774815)
41. Cooper Jr LT, Berry GJ, Shabetai R. Idiopathic giantcell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Eng J Med. 1997;336:1860-6.
42. Menghini VV, Savcenko V, Olson LJ, et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc. 1999;74:1221-6.
43. Cooper Jr LT, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008;102:1535-9.
44. McCarthy 3rd RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis compared with acute (nonfulminant) myocarditis. N Eng J Med. 2000;342:690-5. (Pubitemid 30131421)
45. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36:227-32. (Pubitemid 30466138)
46. Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center's experience. Eur J Cardiothorac Surg. 2011;40(3):682-8.
47. Asaumi Y, Yasuda S, Morii I, et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J. 2005;26(20):2185-92. (Pubitemid 41408005)
48. Ishida K, Wada H, Sakakura K, et al. Long-term follow-up on cardiac function following fulminant myocarditis requiring percutaneous extracorporeal cardiopulmonary support. Heart Vessels. 2011 Dec 28. doi:10.1007/s00380-011- 0211-8
49. Grundeman PF, Tukkie R, Moulijn AC, et al. Shortterm biventricular circulatory support in the regionally stunned pig myocardium. Thorac Cardiovasc Surg. 1993;41:290-6. (Pubitemid 23338899)
50. Jaroszewski DE, Marranca MC, Pierce CN, et al. Successive circulatory support stages: a triple bridge to recovery from fulminant myocarditis. J Heart Lung Transplant. 2009;28:984-6.
51. Colombo T, Garatti A, Bruschi G, et al. First successful bridge to recovery with the Impella Recover 100 left ventricular assist device for fulminant acute myocarditis. Ital Heart J. 2003;4:642-5.
52. Khalife WI, Kar B. The TandemHeart pVAD in the treatment of acute fulminant myocarditis. Tex Heart Inst J. 2007;34:209-13. (Pubitemid 47066600)
53. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90.
54. Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793-8. (Pubitemid 36705988)
55. Costanzo-Nordin MR, Reap EA, O'Connell JB, et al. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol. 1985;6:1078-82. (Pubitemid 16219205)
56. Maron BJ. Sudden death in young athletes. N Eng J Med. 2003;349:1064-75. (Pubitemid 37098275)
57. Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: CM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol. 2005;45:1340-5. (Pubitemid 40523165)
58. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Eng J Med. 1995;333:269-75.
59. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocyticmyocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107:857-63. (Pubitemid 36241044)
60. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30:1995-2002.
61. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39-45. (Pubitemid 32623287)
62. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-9. (Pubitemid 32433714)
63. Herda LR, Trimpert C, Nauke U, et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am Heart J. 2010;159:809-16.
64. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914-31. (Pubitemid 350011209)